A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2013-11-04
Target enrollment:
Participant gender:
Summary
This is a Phase I study which will analyze any food-drug effects as well as QTc effects of
perifosine. Safety and efficacy will also be evaluated.
Patients who complete the first 24 days on single agent perifosine may have the opportunity
to 1) continue on single agent perifosine; 2) switch to the combination of capecitabine +
perifosine; or 3) switch to the combination of sorafenib + perifosine.